Back to Blog

News

What FDA's July 2026 psychedelic-trial guidance means

2026-10-21 · 2 min read

The FDA issued its final psychedelic-drug research guidance in July 2026, replacing the June 2023 draft. It gives sponsors a framework for planning clinical investigations. It does not approve a treatment.

Who the guidance is for

The document addresses sponsors developing psychedelic drugs for medical conditions. Its scope includes clinical trials under an investigational new drug application, including research trials that are not intended to support a marketing application.

The final guidance uses “psychedelic drugs” to include classic psychedelics such as psilocybin and LSD, as well as MDMA. Its considerations cover drug quality, nonclinical research, clinical pharmacology, abuse potential, trial design and participant safety.

What “final” means

Final means that this document replaces the earlier draft. It describes FDA's current recommendations, rather than settling every question about how a particular trial should run. Sponsors can discuss their development plans with the agency.

The guidance itself is nonbinding. Laws and regulations cited in it can impose requirements, but the recommendations do not create a separate approval or permission to offer treatment.

What readers can use it for

If you are following a study, the guidance helps explain the questions its sponsor needs to address. It is not a report of results from that study. A research framework cannot tell you whether a particular treatment worked, whether its benefits outweigh its risks, or whether you qualify to participate.

Those questions require different information. Our guide to trial listings and study results explains the distinction. Our phase-label guide explains what Phase 1, 2 and 3 describe.

You can explore listed studies on the research map. Open the original registry record to check the study's current status, eligibility and contacts.

Sources

• fda.gov (1)
• fda.gov (2)